Antibody‑drug conjugates diversified in 2025 as developers introduced new linkers, payloads and conjugation chemistries to expand target space and therapeutic windows. Industry reports catalog an unusually broad set of next‑generation ADC designs aimed at solid tumors and hematologic malignancies. Hanx Biopharmaceuticals disclosed TRBV12‑targeting ADCs for T‑cell leukemias and lymphomas, reflecting the trend toward tumor‑selective antigens and specialized ADC architectures. The wave of innovation has created multiple partnering and investor touchpoints as companies seek to translate platform advances into differentiated clinical assets.